ArticleOpen forum infectious diseases2025
High Seroprevalence of Hepatitis E Virus Among Patients With Hepatitis B and Those With Hepatitis of Unknown Etiology in Central Vietnam.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Analysis of the epidemiological trends of hepatitis A and E in Zhejiang Province and clinical characteristics of severe patients.BMC infectious diseases · 2026Article
- Hepatitis E virus exposure and risk factors among ethnic minority populations in Northern Vietnam.PloS one · 2026Article
- Low prevalence of concurrent active hepatitis E and B virus infection in high-risk groups in Southwestern Cameroon.IJID regions · 2025Article
- Update on Hepatitis E Virus Infection 2025: Insights From an International Symposium.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis E virus (HEV) is a significant cause of acute viral hepatitis, particularly in regions with poor sanitation. Co-infection with hepatitis B virus (HBV) is common in high-risk populations, such as individuals with chronic liver disease, but data on HEV prevalence in patients living with HBV in Southeast Asia are limited. This study investigates HEV seroprevalence among patients with HBV and those with hepatitis of unknown etiology (HUE) in central Vietnam. Method: Blood samples from 587 patients with HBV and 158 individuals with HUE were collected and analyzed for anti-HEV immunoglobulin G (IgG) and immunoglobulin M antibodies by enzyme-linked immunosorbent assay. HEV RNA was detected using reverse transcriptase-polymerase chain reaction, and HBV viral load was quantified via real-time polymerase chain reaction. Results: The overall anti-HEV IgG seroprevalence was 26% in patients with HBV and 36% in those with HUE. Although patients with liver cirrhosis and hepatocellular carcinoma exhibited higher rates of anti-HEV IgG seropositivity, these differences were not statistically significant. Among patients with HBV, the seroprevalence was highest in those with liver cirrhosis and hepatocellular carcinoma (46%), whereas the lowest (24%) was found in patients with symptomatic chronic hepatitis B. Only 1 (0.1%) tested positive for anti-HEV immunoglobulin M, and no HEV RNA positivity was detected. Furthermore, biochemical laboratory parameters in patients with liver diseases were not found to be associated with anti-HEV seropositivity. Conclusions: Anti-HEV IgG seroprevalence was relatively high among patients with chronic liver disease, including those with HBV. However, no association was observed between HEV exposure and liver disease progression. HEV is not a common cause of hepatitis in Central Vietnam.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.